BMS/Thermocore pact for vulnerable plaque
This article was originally published in The Gray Sheet
Executive Summary
Bristol-Myers Squibb gains worldwide development, manufacturing and commercialization rights to Thermocore intracoronary thermographic catheter system technology designed to detect vulnerable plaque by mapping temperature variations inside coronary arteries. Rupture of vulnerable plaque is a prime cause of heart attack. Initial clinical trials will focus on assessing the prognostic value of the device, according to BMS. During a vulnerable plaque summit at the May CRT 2004 conference in Washington, D.C., participants generally agreed that no accurate imaging tools currently exist to detect vulnerable plaque 1"The Gray Sheet" May 10, 2004, p. 4)...
You may also be interested in...
DES For Vulnerable Plaque: Consensus Elusive With Current Imaging Tools
Drug-eluting stents should not be viewed as the definitive treatment for vulnerable plaque, according to David Holmes, MD, Mayo Clinic
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.